What is REGN(Regeneron Pharmaceuticals) average time for price targets to be met?

On average it took 253.96 days on average for the stock forecasts to be realized with a an average price target met ratio 87.15.

REGN - Regeneron Pharmaceuticals Stock - Displayed [650 Analyst Price Targets]

REGN - Regeneron Pharmaceuticals - Stock Forecast

Healthcare - Sector

Coverage Profile Stock analysts Price Targets & Ratings Chart Insider Trading

REGN is currently covered by 30 analysts with an average price target of $711.28. This is a potential upside of $140.69 (24.66%) from yesterday's end of day stock price of $570.59.

Regeneron Pharmaceuticals's activity chart (see below) currently has 650 price targets and 648 ratings on display. The stock rating distribution of REGN is 76.97% BUY, 20.39% HOLD and 2.63% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 87.15% with an average time for these price targets to be met of 253.96 days.

Highest price target for REGN is $1200, Lowest price target is $547, average price target is $892.1.

Most recent stock forecast was given by TRUNG HUYNH from UBS on 11-Jul-2025. First documented stock forecast 21-Dec-2012.

Overview

Regeneron Pharmaceuticals specializes in products that enable minimally invasive care.

Products

The da Vinci Surgical System is a robotic surgical system that includes:

A console where the surgeon sits and controls the instruments and a high-definition 3D camera.

The surgeon uses the console to control the instruments, which are inserted into the patient’s body through small incisions. The system allows for greater precision and control during surgery, resulting in reduced trauma to the patient and faster recovery times.

The Ion endoluminal system enables minimally invasive biopsies in the lung, which can help diagnose lung cancer and other conditions.

Intuitive Surgical also provides a suite of stapling, energy, and core instrumentation for its surgical systems, as well as progressive learning pathways to support the use of its technology. The company offers a complement of services to its customers, including support, installation, repair, and maintenance, to ensure that its products operate efficiently and effectively.

Moreover, Intuitive Surgical has integrated digital capabilities providing connected offerings that streamline performance for hospitals with program-enhancing insights.

History

The company was founded in 1995 and is headquartered in Sunnyvale, California.

Regeneron Pharmaceuticals in the News

Regeneron’s Lynozyfic Gains Accelerated FDA Approval for Multiple Myeloma

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts. On July 2, the US FDA) granted accelerate approval to Regeneron Pharmaceuticals’s linvoseltamab-gcpt, which is marketed under the brand name Lynozyfic. This bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager is approved for the treatment of adult...

California fails to stop 23andMe founder from re-acquiring company

By Dietrich Knauth (Reuters) -Genetic testing company 23andMe can proceed with a $305 million sale to the company’s co-founder Anne Wojcicki after a U.S. bankruptcy judge rejected California’s bid to delay the sale while the state appeals over privacy concerns related to the deal. U.S. Bankruptcy Judge Brian Walsh, who previously approved Wojcicki’s buyout of the...